The hybridoma cells produced by the fusion of mouse B lymphocytes and myeloma cells can secrete monoclonal antibodies against a single epitope, which can avoid the serological cross reaction between different cells and microbial species or strains, and are widely used in the research of antibody drugs.
DetaiBio provides you with Fast Hybridoma mAb Development customization services. Combinding rapid immunization platform and DeeLight® the cell screening platform, the one-stop service, from antigen preparation to ELISA, FACs and other multi platform verification, can select the best immune scheme according to the nature of the antigen. The Balb/c mice used for immunization are SPF level, with a number of 6-8; Ensure that the ELISA titer of the purified antibody is >1:128000, and the delivered monoclonal antibody can be used in downstream experiments such as immunohistochemistry, ELISA, in vitro diagnostic testing, etc.
|StageⅠ Animal Imunization||2-4 weeks|| Premium Package|
|StageⅡ Hybridoma Cell Fusion||4-5 days|
|Stage Ⅲ DeepLight® Screening||2-3 days|
|Stage Ⅳ Culture Expression & Function Verification|
|Stage Ⅴ Monoclonal Antibody Sequencing (optional)||1 week|
Note: If the customer provides antigen, 6-8mg antigen amount, concentration ≥ 0.5mg/ml, purity ≥ 85%, PBS buffer (without other additives)
Adopt DeepLight® On-chip screening technology can directly screen hybridoma cells that can
secrete functional antibodies.
After purification, SDS-PAGE showed that the antibody had high purity and less heterobands. According to the customer’s requirements, WB test was carried out with the antigen to be tested provided by the customer, and the result was positive.